Difference between revisions of "Renal cell carcinoma - historical"
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...") |
|||
Line 54: | Line 54: | ||
===References=== | ===References=== | ||
# Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. [https://www.nejm.org/doi/10.1056/NEJM200009143431101 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10984562 PubMed] | # Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. [https://www.nejm.org/doi/10.1056/NEJM200009143431101 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10984562 PubMed] | ||
+ | |||
+ | ==Interferon alfa-2a monotherapy {{#subobject:8f04d6|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen {{#subobject:b28245|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 25%" |Study | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 25%" |Comparator | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[http://ascopubs.org/doi/full/10.1200/JCO.2005.07.114 Aass et al. 2005 (EORTC 30951)] | ||
+ | |style="background-color:#1a9851"|Phase III (C) | ||
+ | |IFN alfa-2a & Retinoic acid | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior OS | ||
+ | |- | ||
+ | |} | ||
+ | ====Immunotherapy==== | ||
+ | *[[Interferon alfa-2a (Roferon-A)]] | ||
+ | |||
+ | ===References=== | ||
+ | # '''EORTC 30951:''' Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.07.114 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15961764 PubMed] | ||
==Megestrol acetate monotherapy {{#subobject:4b50ea|Regimen=1}}== | ==Megestrol acetate monotherapy {{#subobject:4b50ea|Regimen=1}}== |
Revision as of 18:50, 23 December 2018
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main RCC page for current regimens.
9 regimens on this page
9 variants on this page
|
Metastatic disease, first-line
Medroxyprogesterone acetate monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Medical Research Council Renal Cancer Collaborators 1999 (MRC RE01) | Phase III (C) | IFN alfa-2a | Seems to have inferior OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Hormonotherapy
References
- Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999 Jan 2;353(9146):14-7. link to original article contans protocol PubMed
Metastatic disease, second-line
FC, then allo HSCT
back to top |
FC: Fludarabine & Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Childs et al. 2000 | Non-randomized, <20 pts |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days -5 to -1
- Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -7 & -6
Immunotherapy
- Allogeneic stem cells transfused on day 0
One course
References
- Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. link to original article contains verified protocol PubMed
Interferon alfa-2a monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Aass et al. 2005 (EORTC 30951) | Phase III (C) | IFN alfa-2a & Retinoic acid | Seems to have inferior OS |
Immunotherapy
References
- EORTC 30951: Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8. link to original article PubMed
Megestrol acetate monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Ravaud et al. 2008 | Phase III (C) | Lapatinib | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. Kelley & Baker 1961 examined a variety of progestins and is included for historic interest.
Hormonotherapy
References
- Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol. 2008 May 10;26(14):2285-91. link to original article PubMed